Evidence map›Paper›PMID 32620409›Full record

Trial reportTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2020

Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia.

Mehmet Ali Erkurt, Ahmet Sarici, İlhami Berber, İrfan Kuku, Emin Kaya, Mustafa Özgül

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Should timing be considered before abandoning convalescent plasma in covid-19? Results from the Turkish experience.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021
    Trial
  11. Trial
  12. Trial
  13. Article
  14. Plasma therapy: a passive resistance against the deadliest.Human vaccines & immunotherapeutics · 2022
    Review
  15. Convalescent Plasma Reduces Endogenous Antibody Response in COVID-19: A Retrospective Cross-Sectional StudyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. The Convalescent Plasma Craze! Where Does India Stand?Journal of laboratory physicians · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mehmet Ali ErkurtInonu University, Turgut Ozal Medical Center, Adult Hematology Department, Malatya, Turkey. Electronic address: erkurtali@hotmail.com.
Ahmet SariciInonu University, Turgut Ozal Medical Center, Adult Hematology Department, Malatya, Turkey. Electronic address: ahmetsarici@inonu.edu.tr.
İlhami BerberInonu University, Turgut Ozal Medical Center, Adult Hematology Department, Malatya, Turkey. Electronic address: ilhami.berber@inonu.edu.tr.
İrfan KukuInonu University, Turgut Ozal Medical Center, Adult Hematology Department, Malatya, Turkey. Electronic address: irfan.kuku@inonu.edu.tr.
Emin KayaInonu University, Turgut Ozal Medical Center, Adult Hematology Department, Malatya, Turkey. Electronic address: emin.kaya@inonu.edu.tr.
Mustafa ÖzgülInonu University, Turgut Ozal Medical Center, Adult Hematology Department, Malatya, Turkey. Electronic address: ranamuz@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimConvalescent Plasma (CP) therapy is of interest as no vaccine or specific treatment is available for emerging viruses such as severe acute respiratory syndrome coronavirus 2 causing Covid-19. It was aimed to report the results of our patients who underwent CP in the treatment of Covid-19.

methodsCP treatment was applied to 26 Covid-19 patients in intensive care unit who had quantitative reverse transcriptase-polymerase chain reaction positive Sars-Cov-2 infection. Plasma was collected at least 14 days after complete recovery from patients who had mild or moderate infection with Sars-Cov-2 infection. The collected CP (200cc) were applied to severe Covid-19 patients. Laboratory values of patients just before CP and after 7 days were compared.

resultsThere were no statistically significant differences in leukocyte, neutrophil, lymphocyte, platelet, CRP, ferritin, LDH, ALT, AST, sO

conclusionCP therapy has the potential to provide immediate and promising treatment options before specific vaccines and treatments are developed. In early stage Covid-19 patients who do not need mechanical ventilation, CP treatment may be a curative treatment option.

Indexed as

AgedCOVID-19COVID-19 SerotherapyFemaleHumansImmunization, PassiveMaleTurkeyConvalescent plasmaCoronavirusCovid-19Immun plasmaSars-Cov-2 infection

Identifiers

PMID32620409
PMCPMC7320698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.